A phase 3, open-label, continuation study evaluating long-term safety and efficacy of belimumab in patients from Japan and Korea with systemic lupus erythematosus, for up to 7 years

Authors
Category Primary study
JournalAnnals of the Rheumatic Diseases
Year 2020
This article has no abstract
Epistemonikos ID: 62b4aa5a006580a5fc0ec08f74d472e41bf3783c
First added on: Feb 12, 2025